Dr. Stuart N. Liberman, MD

Dr. Liberman practices at Health First Medical Group, LLC in Miami, Florida.

Dr. Liberman's NPI, 1790776243, was assigned on November 3, 2005. Dr. Liberman graduated from Emory School of Medicine in 1989. Dr. Liberman holds Florida license ME70778.

Dr. Liberman's primary practice is Health First Medical Group, LLC, at 8370 W Flagler St, Miami, FL 33144 in Miami-Dade County. The practice phone is (321) 434-1981.

Dr. Liberman's primary practice is Health First Medical Group, LLC in Miami, Florida. Dr. Liberman is also affiliated with Cape Canaveral Hospital. The medical group on file is Health First Medical Group (Formerly Mima). Dmand AI also links Dr. Liberman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Liberman practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Liberman's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Liberman is board certified in urology by the American Board of Urology. Dmand AI has Dr. Liberman's licenses on file in 5 states: Florida, Georgia, North Carolina, Pennsylvania and Delaware.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney disease, kidney removal surgery and kidney stone disease among the conditions Dr. Liberman treats.

CMS data shows 7,552 Medicare services from Dr. Liberman across 22 procedure codes in 2024, for 755 Medicare patients. Medicare paid $155,659 for them.

CMS counts 755 Medicare patients who saw Dr. Liberman in 2024. The largest group is 65 to 74, with 365 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Liberman's median patient age at 75, with 13% women.

In 2024, Dr. Liberman wrote 2,009 Medicare Part D claims for 583 patients. 96% of them were for generic drugs. CMS names the drug for 1,817 of them, across 16 drugs with 11 or more claims each, at $99,103 in total drug cost. In 2023, CMS named 1,738 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Liberman for performance year 2024, reported through an alternative payment model (APM). Dr. Liberman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Liberman. The most frequent topics are Prostatic Neoplasms, Antibodies, Monoclonal and Ricin. Dr. Liberman has published most often in Urology. Dr. Liberman's most frequent co-author is Leonard G. Gomella, MD.

CMS Open Payments shows 193 general payments to Dr. Liberman from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Teleflex LLC paid the most, $1,186.

Dmand AI lists 1 award for Dr. Liberman, most recently CMS Stage 1 2012 in 2011.

Dr. Liberman graduated from Emory School of Medicine in 1989.

Dr. Liberman is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.